





Somatropin auto-injector pen

Supporting children as they grow up!

This material is exclusive to HCPs; do not distribute to the general public.



HHT® Pen contains **somatropin**, a human growth hormone produced with **recombinant DNA technology**^{1,2}, which is identical in structure and function to the natural human growth hormone.¹

Physiological Effects of Growth Hormone



Growth hormone has a large number of physiological effects, both directly through its receptor and indirectly by interaction with other hormones.³

The two main effects involve bone and muscle growth, and effects on the metabolism of carbohydrates, proteins, and lipids.³

HHT Pen® is indicated for:

Children

Long-term treatment in pediatric patients with:

- Growth retardation due to growth hormone deficiency^{1,2}
- Growth retardation due to renal impairment^{1,2}
- Prader-Willi syndrome^{1,2}
- Turner syndrome^{1,2}
- Noonan syndrome¹
- IUGR/born small for gestational age with growth retardation, who fail to manifest catch-up growth by two years of age.^{1,2}

Adults

- Replacement therapy in adults with growth hormone deficiency^{1,2}
- Adult patients with AIDS wasting syndrome or cachexia.^{1,2}

EARLY DIAGNOSIS AND INITIATION OF GROWTH HORMONE THERAPY **ARE ESSENTIAL** TO OPTIMIZE TREATMENT EFFECTS.⁴



Benefits of Treatment with HHT®

CLINICAL STUDY RESULTS HAVE SHOWN THAT TREATMENT WITH HHT® IS **SAFE AND EFFECTIVE**.¹

Children with growth hormone deficiency

- > Treatment with HHT® significantly increased baseline growth rate in children with growth hormone deficiency.1
- A sustained improvement was evidenced by the approximation to genetic target height, with a mean recovery of 2 standard deviations over two years of treatment (Figure 1).1

Figure 1

Effect of treatment with HHT® on the height of children with growth hormone deficiency, in terms of distance in standards deviations related to Genetic Target Height¹





Figure 2


Effect of treatment with HHT® on the level of circulating IGF-1 over 2 years of treatment



• Furthermore, treatment with HHT® was associated with a significant increase in IGF-1 (Figure 2), IGFBP3, and ALS levels.¹

Children with Intrauterine Growth Restriction

In children with intrauterine growth restriction who did not spontaneously complete compensatory growth during their first years of life, **treatment with HHT®** significantly improved growth rate (Figure 3), allowing rapid achievement of a height within the normal range with an acceptable safety profile.^{1,5}



The Importance of Treatment Adherence

> Several studies have demonstrated that suboptimal adherence to growth hormone therapy affects its long-term effectiveness, leading to:6



Furthermore, suboptimal treatment adherence could also impact on other clinical results and patients' quality of life.⁷

ADHERENCE TO GROWTH HORMONE TREATMENT IS ESSENTIAL FOR ACHIEVING THERAPEUTIC GOALS.⁶



FIRST ARGENTINE GROWTH HORMONE



SAFE AND PRACTICAL ADMINISTRATION

- User-friendly auto-injector pen for somatropin administration
- It allows for dose adjustment according to age, weight, and diagnosis
- Each 3 mL cartridge contains 20 mg (60 IU) of somatropin
- > 100% liquid formulation

EXTENSIVE CLINICAL USE EXPERIENCE

- Over 20 years of clinical experience in Argentina
- Present in over 17 countries worldwidel

PATIENT BENEFITS

- Improvement in patient's social and emotional life
- Significant metabolic benefits
- Patient-adapted dosing

HHT® PEN PROVIDES
PATIENTS WITH PRECISE,
SAFE, AND CONVENIENT
ADMINISTRATION OF THEIR
RECOMMENDED DOSE OF
SOMATROPIN



100% Liquid Formulation for Use with the Auto-Injector Pen



HHT® PEN BENEFITS GROWTH AND METABOLISM, IMPROVING PATIENTS' SOCIAL AND EMOTIONAL LIFE.

Bio es Vida[®]. Your direct contact.

Bio es Vida[®] is a patient program including:

- Free-of-charge patient starter kit
- Nurse counselling
- Treatment access program



Personalized support line

Abbreviations: AIDS: acquired immunodeficiency syndrome. ALS: acid labile subunit. IGF-1: insulin-like growth factor-1. IGFBP3: insulin-like growth factor binding protein-3. IUGR: intrauterine growth restriction.

References: 1. Product Monograph. HHT® Somatropin. BIOSIDUS S.A. 2. Prescribing Information. HHT® Pen (Somatropin). BIOSIDUS S.A. October 2015. 3. Tidblad A. The history, physiology and treatment safety of growth hormone. Acta Paediatr. 2022 Feb;111(2):215-224. 4. López-Siguero JP, Pfäffle R, et al. Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data. Drug Des Devel Ther. 2017 May 16;11:1489-1495. 5. Bergadá I, Blanco M, et al. Tratamiento con hormona de crecimiento en niños menores de 6 años de edad, con talla baja, nacidos pequeños para la edad gestacional. Arch Argent Pediatr. 2009; 107(5):410-416. 6. Graham S, et al. Exploring Potentially Modifiable Factors That Influence Treatment Non-Adherence Amongst Pediatric Growth Hormone Deficiency: A Qualitative Study. Patient Prefer Adherence. 2020 Oct 13;14:1889-1899. 7. Loftus J, Chen Y, et al. Suboptimal adherence to daily growth hormone in a US real-world study: an unmet need in the treatment of pediatric growth hormone defi-ciency. Curr Med Res Opin. 2021 Dec;37(12):2141-2150.

This material is exclusive to HCPs; do not distribute to the general public.



BIOSIDUS S.A.U. | Constitución 4234 (C1254ABX) C.A.B.A. Corporate Office: Cazadores de Coquimbo 2841, Bldg 4, 1st Floor (B1605AZE) Munro, Buenos Aires | +5411 4909 8000. info@biosidus.com.ar | www.biosidus.com.ar



